Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
investigational drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1370261-97-4
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developer |
gptkb:Pfizer
|
| gptkbp:developmentType |
discontinued
|
| gptkbp:discontinued |
2016
|
| https://www.w3.org/2000/01/rdf-schema#label |
bococizumab
|
| gptkbp:intendedUse |
lowering LDL cholesterol
|
| gptkbp:macromoleculeType |
humanized monoclonal antibody
|
| gptkbp:mechanismOfAction |
inhibits PCSK9 protein
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
gptkb:PCSK9
|
| gptkbp:UNII |
6Q1K1Y1A2E
|
| gptkbp:bfsParent |
gptkb:PCSK9_protein
|
| gptkbp:bfsLayer |
7
|